Xath5 participates in a network of bHLH genes in the developing Xenopus retina [published erratum appears in Neuron 1998 Nov;21(5):following 1221]
AuthorsKanekar S, Perron M, Dorsky R, Harris WA, Jan LY, Jan YN, Vetter ML
JournalNeuron
PubMed ID9390513
'We examined the function of basic-helix-loop-helix (bHLH) transcription factors during retinal neurogenesis. We identified Xath5, a Xenopus bHLH gene related to Drosophila atonal, which is expressed in the developing Xenopus retina. Targeted expression of Xath5 in retinal progenitor cells biased the differentiation of these cells toward a ganglion cell fate, ... More
T cell receptor recognition of MHC class II-bound peptide flanking residues enhances immunogenicity and results in altered TCR V region usage.
AuthorsCarson RT, Vignali KM, Woodland DL, Vignali DA
JournalImmunity
PubMed ID9324359
'Naturally processed MHC class II-bound peptides possess ragged NH2 and COOH termini. It is not known whether these peptide flanking residues (PFRs), which lie outside the MHC anchor residues, are recognized by the TCR or influence immunogenicity. Here we analyzed T cell responses to the COOH-terminal PFR of the H-2A(k) ... More
High-performance subtractive hybridization of cDNAs by covalent bonding between specific complementary nucleotides [In Process Citation]
AuthorsYing SY, Lin S
JournalBiotechniques
PubMed ID10337490
We have developed an improved subtractive hybridization method that provides a fast, simple and reliable isolation of desired different sequences from two compared DNA libraries, one of which contains all unwanted homologues (subtracter) and another contains certain desired heterologues (tester). The DNA library can be made from either mRNA or ... More
Immunogene therapy of tumors with vaccine based on Xenopus homologous vascular endothelial growth factor as a model antigen.
Authors Wei Y Q; Huang M J; Yang L; Zhao X; Tian L; Lu Y; Shu J M; Lu C J; Niu T; Kang B; Mao Y Q; Liu F; Wen Y J; Lei S; Luo F; Zhou L Q; Peng F; Jiang Y; Liu J Y; Zhou H; Wang Q R; He Q M; Xiao F; Lou Y Y; Xie X J; Li Q; Wu Y; Ding Z Y; Hu B; Hu M; Zhang W;
JournalProc Natl Acad Sci U S A
PubMed ID11553767
Overcoming immune tolerance of the growth factors associated with tumor growth should be a useful approach to cancer therapy by active immunity. We used vascular endothelial growth factor (VEGF) as a model antigen to explore the feasibility of the immunogene tumor therapy with a vaccine based on a single xenogeneic ... More